HELP — Cybin Inc.

Is HELP overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Cybin Inc. (HELP) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $11.78. The rating moved from Oversold to Overbought on July 30, 2026.

See all overbought Healthcare stocks →

AI analysis

Cybin Inc. (HELP) is a clinical-stage developer focused on psychedelic-assisted therapies, where valuation is driven by clinical progress, financing cadence, and regulatory signals. The company’s near-term outlook is dominated by binary clinical and regulatory catalysts that can produce sharp upside if positive or steep downside if negative. There is no meaningful current product revenue, so cash runway and potential dilution are central to the financial-health picture. Broader biotech M&A appetite and growing scientific interest in psychedelic modalities provide constructive strategic optionality, but high clinical failure probability, commercialization uncertainty, and limited liquidity keep near-term risk elevated. Monitor upcoming trial milestones, cash balance/financing activity, and any formal regulatory guidance as the primary determinants of directional moves.

Key factors

  • Clinical-stage pipeline with near-term binary catalysts (trial readouts and regulatory interactions) that can drive large share moves
  • Limited or no meaningful product revenue; valuation tied to R&D progress and financing outlook
  • Sector M&A tailwinds: elevated biotech/pharma multiples increase strategic value for successful programs
  • Specialized therapeutic focus (psychedelic-assisted therapies) with growing scientific and commercial interest but evolving regulatory frameworks
  • Market environment is neutral over the past few hours, reducing immediate directional pressure; selective interest in growth names may intermittently benefit the stock

Risks

  • High clinical and regulatory risk: negative trial outcomes, delays, or unfavorable FDA interactions could materially impair valuation
  • Cash burn and dilution risk: need for further financing could lead to equity issuance and downward pressure on the share price
  • Competitive risk from other psychedelic or CNS developers and from alternative therapeutic modalities
  • Limited liquidity and volatile trading typical for small-cap biotech can exacerbate price swings
  • Reimbursement, commercialization and payer uncertainty for novel therapeutic modalities
  • Reputational or policy/regulatory shifts affecting psychedelic therapy development or trial access

See today's live rating, score and targets

Members see the live hourly rating for HELP — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.